Wide range of views about switching to weekly, monthly or biannual ART
Doravirine combination works well as a switch option
Dual-antibody combination therapy produces three to seven months of viral suppression without pills
Two new doravirine pills approved in US
Doravirine maintains higher rate of virological suppression over darunavir/ritonavir though 96 weeks of follow-up
The kick that didn’t kill: first-ever randomised HIV cure study fails to eliminate infected cells
Dolutegravir dual therapy works well for first-time HIV treatment
TAF only superior to TDF when used with a boosting agent
Powerful new PrEP and treatment drug should be effective as a small weekly pill
